natgillin/translations-raw huggingface dataset:
Special warnings and precautions for use Concomitant use with opioids 
Posebna opozorila in previdnostni ukrepi
Talk to your doctor or pharmacist before taking <brand name> 
Pred začetkom jemanja zdravila <lastniško ime> se posvetujte z zdravnikom ali farmacevtom
Rare (may affect up to 1 in 1,000 people): 
Redki (pojavijo se lahko pri največ 1 od 1 000 bolnikov): − težave z dihanjem, plitvo dihanje (respiratorna depresija)
Powder for concentrate for solution for infusion 
5 mg prašek za koncentrat za raztopino za infundiranje intravenska uporaba viala (steklo)
Pack size 
Mylotarg
The patches should not be cut into pieces. 
Ne smejo se rezati na manjše koščke.
The patches can be worn during bathing and hot weather. 
Obliži se lahko nosijo med kopanjem in v vročem vremenu.
Treatment should be continued for as long as the patient benefits from it. 
Zdravljenje je treba nadaljevati, dokler ima bolnik od njega koristi.
The patches are applied to clean, dry, hairless, intact skin on the back, upper arm or chest, and are replaced every 24 hours. 
Obliže je treba prilepiti na čisto, suho, neporaščeno in nepoškodovano kožo na hrbtu, nadlakti ali prsih in zamenjati vsakih 24 ur.
Treatment should continue as long as the medicine has a benefit, but the dose can be reduced or treatment interrupted if the patient has side effects. 
Zdravljenje je treba nadaljevati, dokler ima zdravilo koristi, vendar se lahko odmerek zmanjša ali zdravljenje prekine, če se pri bolniku pojavijo neželeni učinki.
They should not be placed on irritated or red skin, on the thigh or abdomen (tummy), or in places where they will be rubbed by tight clothing. 
Ne smejo se prilepiti na razdraženo ali pordelo kožo, na stegno ali trebuh in na predele, kjer bi se drgnili ob tesna oblačila.
The full EPAR and risk management plan summary for Rivastigmine 3M Health Care Ltd can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Rivastigmin 3M Health Care Ltd sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Rivastigmine 3M Health Care Ltd. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Rivastigmin 3M Health Care Ltd.
Treatment should be started with the 4.6-mg-per-24-hours patch, with the dose increased to the higher strength 9.5 mg/24-h patch after at least four weeks if the lower dose is well tolerated. 
Zdravljenje je treba začeti z obližem, ki v 24 urah sprosti 4,6 mg učinkovine, po najmanj štirih tednih pa je treba odmerek povečati na 9,5 mg/24 ur z uporabo obliža večje jakosti, če bolnik manjši odmerek dobro prenaša.
In patients with Alzheimer's dementia, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a substance that allows nerve cells to communicate with each other). 
Pri bolnikih z Alzheimerjevo demenco nekatere živčne celice v možganih odmrejo, zaradi česar se znižajo ravni živčnega prenašalca acetilholina (kemične snovi, ki omogoča medsebojno komunikacijo
Rivastigmine 3M Health Care Ltd can only be obtained with a prescription and is available as transdermal patches, which release either 4.6 or 9.5 mg rivastigmine across the skin over 24 hours. 
Izdaja zdravila Rivastigmin 3M Health Care Ltd je le na recept, na voljo pa je v obliki transdermalnih obližev, ki v 24 urah skozi kožo sprostijo 4,6 ali 9,5 mg rivastigmina.
Treatment with Rivastigmine 3M Health Care Ltd should be started and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's dementia. 
Zdravljenje z zdravilom Rivastigmin 3M Health Care Ltd mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem Alzheimerjeve demence.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Rivastigmine 3M Health Care Ltd has been shown to have comparable quality and to be bioequivalent to Exelon. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Rivastigmin 3M Health Care Ltd primerljivo raven kakovosti kot referenčno zdravilo Exelon ter da mu je biološko enakovredno.
Because Rivastigmine 3M Health Care Ltd is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Rivastigmin 3M Health Care Ltd generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
The Committee recommended that Rivastigmine 3M Health Care Ltd be approved for use in the EU. 
Priporočil je, da se zdravilo Rivastigmin 3M Health Care Ltd odobri za uporabo v EU.
This means that Rivastigmine 3M Health Care Ltd is similar to a ‘reference medicine' already authorised in the European Union (EU) called Exelon. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Exelon.
Patients can be switched from rivastigmine capsules or oral solution to the patches. 
Bolniki, ki jemljejo kapsule ali peroralno raztopino rivastigmina, lahko preidejo na zdravljenje z obliži.
What measures are being taken to ensure the safe and effective use of Rivastigmine 3M Health Care Ltd? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Rivastigmin 3M Health Care Ltd?
For more information about treatment with Rivastigmine 3M Health Care Ltd, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Rivastigmin 3M Health Care Ltd preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Rivastigmine 3M Health Care Ltd is used to treat patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour. 
Uporablja se za zdravljenje bolnikov z blago do zmerno hudo Alzheimerjevo demenco, tj. napredujočo možgansko boleznijo, ki postopoma prizadene spomin, intelektualno sposobnost in vedenje.
Treatment should only be started if a caregiver is available who will regularly give and monitor the use of Rivastigmine 3M Health Care Ltd by the patient. 
Zdravljenje se sme uvesti samo, če je na voljo negovalec, ki bo redno dajal zdravilo Rivastigmin 3M Health Care Ltd in spremljal njegovo uporabo pri bolniku.
The European Commission granted a marketing authorisation valid throughout the European Union for Rivastigmine 3M Health Care Ltd on 3 April 2014. 
Evropska komisija je dovoljenje za promet z zdravilom Rivastigmin 3M Health Care Ltd, veljavno po vsej Evropski uniji, izdala 03. aprila 2014.
The active substance in Rivastigmine 3M Health Care Ltd, rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase. 
Zdravilna učinkovina v zdravilu Rivastigmin 3M Health Care Ltd, rivastigmin, deluje tako, da zavira encime, ki razgrajujejo acetilholin: acetilholinesterazo in butirilholinesterazo.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Rivastigmine 3M Health Care Ltd, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Rivastigmin 3M Health Care Ltd in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Because Rivastigmine 3M Health Care Ltd is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Exelon. 
Ker je zdravilo Rivastigmin 3M Health Care Ltd generično zdravilo, so bile študije pri ljudeh omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Exelon.
Other information about Rivastigmine 3M Health Care Ltd 
Druge informacije o zdravilu Rivastigmin 3M Health Care Ltd
By blocking these enzymes, Rivastigmine 3M Health Care Ltd allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer's dementia. 
Zdravilo Rivastigmin 3M Health Care Ltd z zaviranjem teh encimov povzroči, da se ravni acetilholina v možganih zvišajo, zaradi česar se simptomi Alzheimerjeve demence ublažijo.
Rivastigmine 3M Health Care Ltd is a medicine that contains the active substance rivastigmine. 
Rivastigmin 3M Health Care Ltd je zdravilo, ki vsebuje zdravilno učinkovino rivastigmin.
For practical information about using Rivastigmine 3M Health Care Ltd, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Rivastigmin 3M Health Care Ltd naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Therefore, the CHMP's view was that, as for Exelon, the benefit outweighs the identified risk. 
Zato je menil, da njegove koristi enako kot pri zdravilu Exelon odtehtajo znana tveganja.
A risk management plan has been developed to ensure that Rivastigmine 3M Health Care Ltd is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Rivastigmin 3M Health Care Ltd je bil pripravljen načrt obvladovanja tveganj.
Rivastigmine 3M Health Care Ltd is a ‘generic medicine'. 
Zdravilo Rivastigmin 3M Health Care Ltd je „generično zdravilo“.
What is Rivastigmine 3M Health Care Ltd and what is it used for? 
Kaj je zdravilo Rivastigmin 3M Health Care Ltd in za kaj se uporablja?
What are the benefits and risks of Rivastigmine 3M Health Care Ltd? 
Kakšne so koristi in tveganja, povezani z zdravilom Rivastigmin 3M Health
Why is Rivastigmine 3M Health Care Ltd approved? 
Zakaj je bilo zdravilo Rivastigmin 3M Health Care Ltd odobreno?
The full EPAR for the reference medicine can also be found on the Agency's website. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za referenčno zdravilo je tudi na voljo na
How does Rivastigmine 3M Health Care Ltd work? 
Kako zdravilo Rivastigmin 3M Health Care Ltd deluje?
How has Rivastigmine 3M Health Care Ltd been studied? 
Kako je bilo zdravilo Rivastigmin 3M Health Care Ltd raziskano?
How is Rivastigmine 3M Health Care Ltd used? 
Kako se zdravilo Rivastigmin 3M Health Care Ltd uporablja?
Article 35 of Directive 2001/82/EC, as amended. 
Člen 35 Direktive 2001/82/ES, kakor je bila spremenjena.
The CVMP was requested to give its opinion on the matter. 
CVMP je bil naprošen, da o zadevi izrazi svoje mnenje.
International Non-Proprietary Name (INN): Ivermectin 
Mednarodno nelastniško ime (INN): ivermektin
The final opinion was converted into a Decision by the European Commission on 1 October 2009. 
Končno mnenje je bilo spremenjeno v Odločbo Evropske komisije dne 1 oktobra 2009.
1 October 2009 Doc. 
1 oktober 2009 Sklic dok.
The referral procedure started on 16 January 2008. 
Napotitveni postopek se je začel 16. januarja 2008.
Ref. EMEA/471056/2009 
: EMEA/471056/2009
The submitted information concerned 173 of the 293 Marketing Authorisations involved in this referral procedure. 
Predložene informacije so zadevale 173 od 293 dovoljenj za promet, ki jih obravnava zadevni napotitveni postopek.
On 9 December 2008 and 14 January 2009 two Marketing Authorisation Holders provided oral explanations at their request. 
9. decembra 2008 in 14. januarja 2009 sta dva imetnika dovoljenj za promet na njihovo zahtevo podala ustna pojasnila.
On 4 June 2008 the National Competent Authorities of the Member States were requested to provide the missing information for the outstanding 120 Marketing Authorisations. 
4. junija 2008 so bili nacionalni pristojni organi držav članic naprošeni, naj priskrbijo manjkajoče informacije za preostalih 120 dovoljenj za promet.
National Marketing Authorisations for injectable products containing ivermectin for use in cattle have been granted in all the Member States of the European Union via different authorisation procedures (mutual recognition procedures or national procedures) and under various legal bases. 
Nacionalna dovoljenja za promet z zdravili za injiciranje, ki vsebujejo ivermektin za uporabo pri govedu, so bila odobrena v vseh državah članicah Evropske unije z različnimi postopki izdaje dovoljenj (postopki medsebojnega priznavanja ali nacionalnimi postopki) ali v skladu z različnimi pravnimi podlagami.
On 17 September 2008 the CVMP considered that there were still issues with regard to some products which needed further clarification and therefore the Committee requested the relevant Marketing Authorisation Holders to address the outstanding issues in writing. 
17. septembra 2008 je CVMP menil, da nekatera vprašanja v zvezi z nekaterimi zdravili še ostajajo in zahtevajo nadaljnja pojasnila, zato je Odbor zadevne imetnike dovoljenj za promet zaprosil, naj pisno pojasnijo preostala vprašanja.
Based on the evaluation of the currently available data and the rapporteurs' assessment, the CVMP considered that its opinion of 11 February 2009 should be revised. 
Na podlagi ovrednotenja trenutno razpoložljivih podatkov in poročevalčevih ocen je CVMP menil, da je treba mnenje z dne 11. februarja 2009 revidirati.
During its 10-12 March 2009 meeting, the CVMP, appointed Dr A. Holm as rapporteur and Dr M. Holzhauser-Alberti as co-rapporteur for the re-examination of the above mentioned opinion. 
Na zasedanju CVMP od 10. do 12. marca 2009 je bil dr. A. Holm imenovan za poročevalca in dr. M. Holzhauser-Alberti za soporočevalca v postopku ponovne presoje zgoraj omenjenega mnenja.
On 25 February 2009, Norbrook Laboratories Ltd, notified the EMEA of its intention to request the reexamination of the CVMP opinion of 11 February 2009. 
Dne 25. februarja 2009 je družba Norbrook Laboratories Ltd obvestila agencijo EMEA, da namerava zaprositi za ponovno presojo mnenja CVMP z dne 11. februarja 2009.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amended Summary of Product Characteristics, package leaflet and label in the Annex III. 
Seznam zadevnih imen proizvodov je naveden v Dodatku I. Znanstveni zaključki so podani v Dodatku II, skupaj s spremenjenim povzetkom glavnih značilnosti zdravila, označevanjem in navodilom za uporabo v Dodatku III.
Due to concerns that the difference in withdrawal periods established across the European Union for injectable veterinary medicinal products containing ivermectin which are indicated for use in cattle and with a dose of 200µg ivermectin/kg bodyweight may present a potential serious risk to human health, the United Kingdom referred the matter to the EMEA on 14 December 2007, under Article 35 of Directive 2001/82/EC. 
Zaradi zaskrbljenosti, da bi lahko razlike v karencah, določenih v različnih državah Evropske unije za veterinarska zdravila za injiciranje, ki vsebujejo ivermektin in so indicirana za uporabo pri govedu v odmerku 200µg ivermektina/kg telesne mase, utegnile predstavljati morebitno resno tveganje za zdravje ljudi, je Združeno kraljestvo zadevo napotilo na agencijo EMEA dne 14. decembra 2007, v skladu s členom 35 Direktive 2001/82/ES.
Eighteen Member States responded and submitted information concerning 103 of the outstanding 120 Marketing Authorisations. 
Odgovorilo je 18 držav članic in predložilo informacije v zvezi s 103 od manjkajočih 120 dovoljenj za promet.
The Committee appointed Dr G. J. Schefferlie as rapporteur and Dr J. G. Beechinor, Prof C. Friis, Prof R. Kroker and Dr B. Urbain as co-rapporteurs. 
Schefferlie je bil imenovan za poročevalca, dr. J. G. Beechinor, prof. C. Friis, prof. R. Kroker and dr. B. Urbain pa za soporočevalce.
On 21 May 2008 the EMEA received a total of 19 written explanations from the Marketing Authorisation Holders (either as a group of or individual Marketing Authorisation Holders). 
21. maja 2008 je EMEA od imetnikov dovoljenj za promet z zdravilom (skupinskih ali posameznih imetnikov dovoljenj za promet) prejela skupaj 19 pisnih obrazložitev.
Written explanations were provided by the Marketing Authorisation Holders on 13 November 2008. 
Imetniki dovoljenja za promet z zdravilom so pisna pojasnila predložili dne 13. novembra 2008.
Ivermectin belongs to the macrocyclic lactone class of endectocides with activity against a wide rage of internal and external parasites. 
Ivermektin sodi v skupino makrocikličnih laktonov v okviru endektocitov, ki delujejo proti številnim vrstam notranjih in zunanjih parazitov.
Further to the resignation of Prof R. Kroker as CVMP member, Dr C. Ibrahim was appointed to replace him and took over the co-rapporteurship. 
Ker je prof. R. Kroker odstopil z mesta člana odbora CVMP, je bil na njegovo mesto imenovan dr. C. Ibrahim, ki je prevzel soporočevalstvo.
Injectable veterinary medicinal products containing ivermectin, either as a single active substance or in combination with a second active substance are indicated for use in cattle for the treatment of endoparasitic and ectoparasitic infestations. 
Veterinarska zdravila za injiciranje, ki vsebujejo ivermektin, bodisi kot samostojno zdravilno učinkovino ali v kombinaciji z drugo zdravilno učinkovino so indicirana za uporabo pri govedu za zdravljenje endoparazitskih in ektoparazitskih okužb.
OPINION FOLLOWING AN ARTICLE 351 REFERRAL FOR Injectable veterinary medicinal products containing ivermectin that are indicated for use in cattle at dose of 200 μg ivermectin per kg bodyweight 
MNENJE V ZVEZI Z NAPOTITVIJO V SKLADU S ČLENOM 351 ZA zdravila za uporabo v veterinarski medicini za injiciranje, ki vsebujejo ivermektin in so indicirana za uporabo pri govedu v odmerku 200 μg ivermektina na kg telesne mase
Based on the evaluation of the currently available data and the rapporteurs' assessment, the CVMP considered that a single withdrawal period of 49 days should be established for all concerned injectable products for cattle containing ivermectin. 
Na podlagi ovrednotenja trenutno razpoložljivih podatkov in ocene poročevalcev je CVMP menil, da bi morala biti za vsa zdravila za injiciranje za govedo, ki vsebujejo ivermektin, določena enotna karenca 49 dni.
Therefore, the Committee adopted an opinion on 11 February 2009 recommending the variation of the existing Marketing Authorisations in accordance with the recommended amendments to the Summary of Product Characteristics. 
Zato je Odbor dne 11. februarja 2009 sprejel mnenje, v katerem je priporočil spremembo obstoječega dovoljenja za promet v skladu s predlaganimi dopolnitvami povzetka glavnih značilnosti zdravila.
Oral explanations were given on 12 May 2009. 
Postopek se je začel 15. aprila 2009. 12. maja 2009 so bila podana ustna pojasnila.
Therefore, the Committee adopted by written procedure an opinion on 5 June 2009 recommending the variation the existing Marketing Authorisations in line with the proposed amendments of the Summary of Product Characteristics, labelling and package leaflet. 
Zato je Odbor dne 5. junija 2009 s pisnim postopkom sprejel mnenje, v katerem je priporočil spremembo obstoječih dovoljenj za promet v skladu s predlaganimi dopolnitvami povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo.
With regard to the products containing ivermectin in combination with clorsulon as a second active substance a withdrawal period of 66 days for cattle was recommended. 
Za zdravila, ki vsebujejo ivermektin v kombinaciji s klorsulonom kot drugo zdravilno učinkovino pa je bila za govedo priporočena karenca 66 dni.
The withdrawal period of 49 days for cattle would also apply to all concerned injectable products containing ivermectin in combination with closantel as a second active substance. 
Enaka karenca 49 dni za govedo bi veljala tudi za vsa zadevna zdravila za injiciranje, ki vsebujejo ivermektin kombinaciji s klosantelom kot drugo zdravilno učinkovino.
The Committee confirmed that a withdrawal period of 49 days should be established for all concerned injectable products for cattle containing ivermectin as a single active substance. 
Odbor je potrdil, da je treba določiti karenco 49 dni za vsa zadevna zdravila za govedo, ki vsebujejo ivermektin kot edino zdravilno učinkovino.
The detailed grounds for the re-examination were submitted by Norbrook Laboratories Ltd on 14 April 2009. 
Družba Norbrook Laboratories Ltd je 14. aprila 2009 predložila podrobnosti, na podlagi katerih je zahtevala ponovno presojo.
The main measure of effectiveness was based on the reduction in the number of episodes of laughing or crying. 
Glavno merilo učinkovitosti je temeljilo na zmanjšanju števila epizod smeha ali joka.
The CHMP also noted that there is currently no treatment available for this distressing condition. 
Upošteval je tudi, da trenutno ni na voljo nobenega zdravljenja za to obremenjujočo bolezen.
The European Commission granted a marketing authorisation valid throughout the European Union for Nuedexta on 24 June 2013. 
Evropska komisija je dovoljenje za promet z zdravilom Nuedexta, veljavno po vsej Evropski uniji, odobrila Dne 24. Junija 2013.
Nuedexta must not be used in patients: 
Zdravilo Nuedexta se ne sme uporabljati pri bolnikih:
The main safety issues were considered manageable and adequately addressed by risk minimisation measures. 
Glavna varnostna tveganja naj bi bila obvladljiva in ustrezno nadzorovana z ukrepi za zmanjšanje tveganja.
The study also measured the change in the patients' symptoms, assessed in several ways including using a standard scale (called a CNS-LS score which ranges from 7 to 35). 
V študiji so merili tudi spremembe simptomov pri bolnikih, ki so jih ocenjevali na več načinov, vključno s standardno lestvico (imenovano lestvica CNS-LS z rezultati od 7 do 35).
The full EPAR for Nuedexta can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Nuedexta je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
• who are taking or have taken within the last 14 days medicines for depression called monoamine oxidase inhibitors (MAOI). 
• ki jemljejo ali so v zadnjih 14 dneh jemali zdravila proti depresiji, imenovana zaviralci monoaminoksidaze (MAOI).
This is a summary of the European public assessment report (EPAR) for Nuedexta. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Nuedexta.
Serious side effects reported include muscle spasticity (excessive stiffness of muscles), respiratory depression (inhibition of breathing) and decreased oxygen saturation (lower-than-normal levels of oxygen) in the blood. 
Resni neželeni učinki, o katerih so poročali, vključujejo mišično spastičnost (prekomerna otrdelost mišic), respiratorno depresijo (ovirano dihanje) in zmanjšano nasičenost s kisikom (nižje ravni kisika od običajnih) v krvi.
• who are taking the medicine thioridazine used for mental illness; 
• ki jemljejo tioridazin, ki se uporablja za zdravljenje duševnih bolezni;
• with ‘prolonged QT interval' (a disruption of the electrical activity of the heart); 
• s „podaljšanim intervalom QT (motnjo električne aktivnosti srca);
In patients whose response is inadequate after four weeks, the higher strength capsule (23mg/9mg) may be used twice a day. 
Bolniki, katerih odziv je po štirih tednih nezadosten, lahko jemljejo kapsulo večje jakosti (23 mg/9 mg) dvakrat na dan.
PBA is a condition where damage to certain areas of the brain results in sudden and uncontrollable episodes of crying or laughing that do not relate to the patient's real emotional state. 
PBP je bolezen, pri kateri se zaradi poškodb nekaterih delov možganov pojavijo nenadne epizode joka ali smeha, ki jih ni mogoče nadzorovati in niso povezane z bolnikovim dejanskim čustvenim stanjem.
Other information about Nuedexta 
Druge informacije o zdravilu Nuedexta